1
|
Opollo V, Sun X, Lando R, Miyahara S, Torres TS, Hosseinipour MC, Bisson GP, Kumwenda J, Gupta A, Nyirenda M, Katende K, Suryavanshi N, Beulah F, Shah NS. The effect of TB treatment on health-related quality of life for people with advanced HIV. Int J Tuberc Lung Dis 2021; 24:910-915. [PMID: 33156757 DOI: 10.5588/ijtld.19.0716] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND: Study A5274 was an open-label trial of people with HIV (PLHIV) with CD4 cell count <50 cells/µL who were randomized to empirical TB treatment vs. isoniazid preventive therapy (IPT) in addition to antiretroviral therapy (ART). We evaluated health-related quality of life (HRQoL) by study arm, changes over time, and association with sociodemographic and clinical factors.METHODS: Participants aged >13 years were enrolled from outpatient clinics in 10 countries. HRQoL was assessed at Weeks 0, 8, 24 and 96 with questions about daily activity, hospital or emergency room visits, and general health status. We used logistic regression to examine HRQoL by arm and association with sociodemographic and clinical factors.RESULTS: Among 850 participants (424 empiric arm, 426 IPT arm), HRQoL improved over time with no difference between arms. At baseline and Week 24, participants with WHO Stage 3 or 4 events, or those who had Grade 3 or 4 signs/symptoms, were significantly more likely to report poor HRQoL using the composite of four HRQoL measures.CONCLUSION: HRQoL improved substantially in both arms during the study period. These findings show that ART, TB screening, and IPT can not only reduce mortality, but also improve HRQoL in PLHIV with advanced disease.
Collapse
Affiliation(s)
- V Opollo
- Kenya Medical Research Institute, HIV-Research Branch, Kisumu, Kenya
| | - X Sun
- Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - R Lando
- Kenya Medical Research Institute, HIV-Research Branch, Kisumu, Kenya
| | - S Miyahara
- Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - T S Torres
- Instituto Nacional de Infectologia Evandro Chagas (INI-FIOCRUZ), Rio de Janeiro, RJ, Brazil
| | - M C Hosseinipour
- University of North Carolina School of Medicine, Chapel Hill, NC, USA, University of North Carolina Project, Lilongwe, Malawi
| | - G P Bisson
- Perlman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | | | - A Gupta
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | | | - K Katende
- Joint Clinical Research Centre Clinical Research Site, Kampala, Uganda
| | - N Suryavanshi
- Byramjee Jeejeebhoy Government Medical College Clinical Trials Unit, Pune, India
| | - F Beulah
- YR Gaitonde Centre for AIDS Research and Education, Chennai Antiviral Research and Treatment Clinical Research Site, Chennai, India
| | - N S Shah
- Centers for Disease Control and Prevention, Atlanta, GA, USA
| |
Collapse
|